Last Updated: November 16, 2026

Patent: 5,547,853

« Back to Dashboard


Summary for Patent: 5,547,853
Title: CD2-binding domain of lymphocyte function associated antigen 3
Abstract:Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.
Inventor(s): Wallner; Barbara P. (Cambridge, MA), Miller; Glenn T. (Haverhill, MA), Rosa; Margaret D. (Winchester, MA)
Assignee: Biogen, Inc. (Cambridge, MA)
Application Number:07/940,861
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 5,547,853: Claim Scope, Expiration, CD2/LFA-3 Patent Landscape, and Commercial Relevance

United States Patent 5,547,853, directed to recombinant LFA-3/CD58 polypeptides and CD2-binding fusion proteins, was a foundational patent for the LFA-3-Ig technology later commercialized as alefacept (Amevive). Its claims cover defined LFA-3-derived peptides, encoding DNA, recombinant production systems, CD2-binding multimeric proteins, diagnostic uses, pharmaceutical compositions, and immunoglobulin Fc fusion proteins.

The patent issued on August 20, 1996. Because it belongs to the pre-Uruguay Round Agreements Act patent-term framework, its ordinary term was generally 17 years from issuance, placing its expected expiration on August 20, 2013, absent a patent-term adjustment, extension, or terminal disclaimer that would alter the calculation. The claims therefore no longer provide enforceable U.S. patent exclusivity.

What technology does United States Patent 5,547,853 cover?

The patent claims engineered fragments of human LFA-3, also known as CD58, that bind CD2. CD2 is a cell-surface receptor expressed on T cells and natural killer cells. LFA-3/CD58 is its principal ligand on antigen-presenting and other cells.

The patent is built around four technical concepts:

  1. Short and extended LFA-3-derived CD2-binding polypeptides.
  2. DNA molecules encoding those polypeptides.
  3. Recombinant production of the proteins in transformed host cells.
  4. Dimeric or multimeric fusion proteins, particularly LFA-3-Ig constructs containing an immunoglobulin Fc region.

The claimed sequence architecture includes the central sequence:

Asn-Arg-Val-Tyr-Leu-Asp-Thr-Val-Ser-Gly

This sequence is identified as SEQ ID NO:1 and is flanked by optional amino-terminal and carboxy-terminal sequences derived from LFA-3. The patent also claims shorter products, including SEQ ID NO:7:

Lys-Asn-Arg-Val-Tyr-Leu-Asp-Thr-Val-Ser-Gly-Ser-Leu-Thr-Ile-Tyr

The claims are functional as well as structural. The relevant product must be “capable of binding to CD2.” That limitation narrows the claims to molecules with demonstrated or legally provable CD2-binding activity, but it also creates potential litigation issues concerning assay conditions, binding affinity, and whether a sequence variant falls within the claimed functional boundary.

How are the claims organized?

Claim group Claims Principal subject matter Commercial significance
CD2-binding polypeptides 1-4 Defined LFA-3-derived sequences and fragments Covers isolated binding domains and peptide-sized constructs
Multimers and uses 5-8 Multimeric proteins, labeling methods, compositions, diagnostic kits Covers research and diagnostic implementations
Encoding DNA 9 DNA encoding claimed polypeptides Extends protection to genetic constructs
Recombinant expression 10-12 Expression vectors, production methods, host cells Covers recombinant manufacturing
CD2-binding domain DNA 13-18 Specific nucleotide sequence, plasmid inserts, vectors and hosts Protects disclosed clones and production systems
Fusion proteins 19-23 LFA-3-derived amino-terminal region linked to another protein domain Core platform for LFA-3-Ig products
Fusion DNA and production 24-30 Fusion-protein genes, vectors, plasmids, host cells and methods Covers product manufacture
Multimeric fusion proteins and uses 31-35 Multimeric fusion products, pharmaceutical and diagnostic uses Covers avidity-enhanced CD2-binding molecules

Claims 1 and 2 are genus claims. They permit optional amino-terminal methionine, optional LFA-3-derived amino-terminal sequence, the SEQ ID NO:1 core, and optional carboxy-terminal extensions. Claim 2 is narrower because it limits the flanking sequences to defined regions corresponding to SEQ ID NO:2 and SEQ ID NO:3.

Claims 3 and 4 are more readily analyzed as sequence-defined species claims. Claim 4 is particularly narrow because it recites the exact 16-residue sequence of SEQ ID NO:7.

Claims 19 through 23 are commercially important because they extend the invention from isolated peptides to fusion proteins. Claim 20 specifies an immunoglobulin Fc region, while claims 21 and 22 further define hinge, CH2, and CH3 components. Claim 23 identifies a particular sequence segment, amino acids 29-347 of SEQ ID NO:43.

What are the strongest and weakest claim categories?

Strongest claims: exact fusion constructs and disclosed DNA

Claims 23, 28, and related claims directed to specifically disclosed sequences or plasmids are the most technically definite. A claim directed to a particular LFA-3-Ig sequence or named plasmid generally presents fewer claim-construction disputes than a broad functional genus.

Claims 13 and 15 also have relatively concrete subject matter because they identify a nucleotide sequence or particular DNA inserts. Their practical value depends on whether the accused product uses the same sequence, a covered fragment, or a substantially different sequence encoding an equivalent CD2-binding domain.

Broad but vulnerable claims: functional peptide genera

Claims 1, 2, 9(a), 9(b), and 19(a)-(b) use a combination of:

  • A defined sequence core;
  • Optional amino-terminal and carboxy-terminal extensions;
  • “A portion thereof” language; and
  • The functional requirement of CD2 binding.

This drafting approach creates potentially broad coverage, but it also raises written-description, enablement, indefiniteness, and claim-construction questions. The “portion thereof” language must be read in the context of the specified terminal direction and amino-acid range. A fragment is not automatically covered merely because it derives from LFA-3; it must satisfy the structural limitations and the CD2-binding requirement.

Weaker commercial claims: compositions, kits, labeling, and generic production claims

Claims 6 through 8, 11, 12, 17, 18, 26, 27, and 29 through 34 are implementation claims. They are useful as fallback claims, but their practical value is usually lower than a direct product claim.

A pharmaceutical composition claim does not necessarily capture every commercial formulation containing an LFA-3-derived molecule. The accused composition must include a covered polypeptide or fusion protein. A diagnostic-kit claim similarly depends on use of the specified CD2-binding reagent and the recited detection architecture.

What does claim 35 add to the patent?

Claim 35 covers a multimeric protein comprising:

  • One or more claimed LFA-3-derived polypeptides; and
  • One or more fusion proteins containing the claimed LFA-3-derived amino-terminal region linked to a non-LFA-3 protein domain.

This claim is directed to mixed multimeric architectures rather than a single LFA-3-Ig molecule. Its commercial relevance lies in avidity. Multiple CD2-binding domains can increase apparent binding strength and alter pharmacokinetics, valency, receptor clustering, and immune-cell engagement.

The claim is also more structurally complex than claims 19 through 23. Litigation would likely focus on whether the accused molecule contains both required categories of components and whether the non-LFA-3 domain is part of a qualifying fusion protein.

How does the patent relate to alefacept?

Alefacept is a recombinant LFA-3-Ig fusion protein designed to bind CD2 and inhibit T-cell activation. The FDA approved Amevive in 2003 for the treatment of adults with moderate-to-severe chronic plaque psoriasis who were candidates for systemic therapy or phototherapy. The product consisted of an LFA-3-derived extracellular binding region fused to a human IgG1 Fc region.[2]

The relationship between the patent and alefacept is direct at the platform level:

Patent element Alefacept relationship
LFA-3-derived CD2-binding region Core biological targeting domain
Immunoglobulin Fc fusion Provides dimerization and extended serum persistence
Multimeric CD2-binding protein Consistent with the bivalent LFA-3-Ig format
Recombinant DNA and host-cell production Required for commercial biologic manufacture
Pharmaceutical composition Covers product-level implementation, subject to claim scope

The patent should not be treated as establishing that every LFA-3-Ig molecule is identical to alefacept. Product coverage depends on the exact amino-acid sequence, domain boundaries, linker, Fc isotype, hinge configuration, glycosylation, and other structural details.

When did United States Patent 5,547,853 lose exclusivity?

The patent issued on August 20, 1996. Under the pre-URAA term applicable to many applications filed before June 8, 1995, the baseline term was 17 years from issuance. On that basis, the patent expired on August 20, 2013.

Event Date or status
Patent issued August 20, 1996
Baseline statutory term 17 years from issuance
Expected ordinary expiration August 20, 2013
Current enforceability Expired
Current U.S. blocking position No active exclusivity from this patent

The patent’s expiration eliminates infringement risk based solely on this patent. It does not eliminate risk from later patents covering specific alefacept formulations, manufacturing processes, combination treatments, dosing regimens, or unrelated CD2-binding biologics.

Patent expiration also does not eliminate regulatory exclusivity. Regulatory exclusivity is separate from patent rights. For alefacept, the original U.S. biologic approval was not protected indefinitely by the patent term, and the product was later withdrawn from the U.S. market. The FDA has not approved a biosimilar to alefacept.[2][3]

What is the Orange Book status of this patent?

United States Patent 5,547,853 is not expected to have an Orange Book listing because Orange Book patent listings principally concern approved small-molecule drug products and certain related products listed under FDA procedures. Alefacept was a biologic licensed under the Public Health Service Act rather than a conventional Orange Book small-molecule product.

The relevant regulatory framework is the Biologics Price Competition and Innovation Act, which created the biosimilar pathway under section 351(k) of the Public Health Service Act. A biologic such as alefacept is generally evaluated through the Purple Book and biologics-licensure framework rather than through an Orange Book Paragraph IV certification process.[3][4]

Are there Paragraph IV challenges to this patent?

No current Paragraph IV challenge can create a meaningful market barrier based on this patent because the patent expired in 2013 and was not the type of active Orange Book-listed patent ordinarily addressed through a Paragraph IV certification.

Paragraph IV litigation is primarily associated with abbreviated new drug applications for small-molecule products. A follow-on alefacept product would ordinarily raise biosimilar, interchangeability, reference-product exclusivity, and biologics-licensure issues rather than a conventional Paragraph IV dispute under the Hatch-Waxman framework.[3][4]

What formulation patents protect alefacept or LFA-3-Ig products?

The claims supplied for Patent 5,547,853 do not contain a detailed formulation patent. Claim 7 covers a pharmaceutical composition comprising a claimed polypeptide and pharmaceutically acceptable carrier. Claim 33 provides a corresponding composition claim for a fusion protein.

These claims are broad composition claims, not detailed formulation claims. They do not specify:

  • A particular buffer system;
  • A defined pH range;
  • Stabilizing sugars or surfactants;
  • A concentration range;
  • A lyophilized presentation;
  • A prefilled syringe;
  • A storage temperature;
  • A container-closure system; or
  • A specific aggregation-control process.

A later patent could therefore protect a particular LFA-3-Ig formulation without being anticipated or exhausted by the generic composition language in claim 33. Conversely, the expired claim 33 cannot block a current product merely because it contains an LFA-3-Ig molecule and a pharmaceutically acceptable carrier.

What manufacturing and intellectual-property barriers remain?

The principal barriers after expiration are technical and regulatory rather than exclusivity based on Patent 5,547,853.

Protein folding and disulfide formation

LFA-3-derived fragments contain sequence-dependent structural requirements. Fusion to Fc changes folding, dimerization, glycosylation, aggregation, and clearance. A follow-on manufacturer must establish a reproducible product with a well-characterized higher-order structure.

Glycosylation and product comparability

A biosimilar or follow-on biologic must address glycosylation, charge variants, aggregates, host-cell proteins, residual DNA, potency, and immunogenicity. The primary sequence alone does not establish biosimilarity.

CD2-binding potency

The relevant biological activity is not limited to analytical identity. A manufacturer must show binding to CD2 and a suitable cell-based or biochemical potency relationship. Differences in Fc-mediated activity may be material, depending on the product design and intended mechanism.

Cell-line and process controls

Claims 10 through 18 and 24 through 30 cover recombinant production concepts, but those claims are expired. Current barriers may arise from proprietary cell lines, process know-how, analytical methods, manufacturing capacity, or later process patents.

How does this patent compare with later CD2 and LFA-3 patent estates?

Estate category Typical protection Status relative to Patent 5,547,853
Foundational LFA-3 sequence claims CD2-binding fragments and sequences Patent 5,547,853 is expired
LFA-3-Ig fusion architecture Fc-linked CD2-binding proteins Core claims expired; later molecule-specific claims may differ
Formulation patents Buffers, stabilizers, concentration and storage Must be assessed patent by patent
Manufacturing patents Cell lines, purification and viral-clearance processes Potentially separate and later-expiring
Method-of-use patents Psoriasis, immune disorders, dosing and combinations Separate from composition claims
Biosimilar regulatory rights Reference-product exclusivity and FDA approval pathway Controlled by biologics law, not this patent
Competing CD2-targeted products Anti-CD2 antibodies or alternative immune modulators Usually outside the literal LFA-3 sequence claims

The patent is therefore best characterized as an expired foundational platform patent. It is important for historical freedom-to-operate analysis and technology provenance, but it is not a current U.S. exclusionary right.

What litigation and settlement issues remain relevant?

A current litigation assessment would not treat infringement of Patent 5,547,853 as a viable standalone claim because the patent expired. Historical litigation could still matter for:

  • Ownership and inventorship disputes;
  • License interpretation;
  • Royalty accounting;
  • Patent-term calculations;
  • Validity of related continuation or divisional patents;
  • Settlement obligations that survived expiration; and
  • Trade-secret or confidential-information claims concerning manufacturing.

Patent expiration does not automatically terminate every contractual obligation. A settlement agreement, license, or supply agreement may contain terms extending beyond the patent term, although contractual restrictions cannot revive an expired patent right against third parties.

How strong was the patent estate?

Historically, the estate was strong at the platform level because it combined sequence, DNA, recombinant production, fusion-protein, multimer, pharmaceutical-composition, and diagnostic-use claims. This created multiple infringement theories against a commercial LFA-3-Ig product.

Its principal weaknesses were claim breadth and functional dependence. The broad claims rely on optional terminal regions, “portions thereof,” and CD2-binding activity. Those limitations can create disputes over written description, enablement, indefiniteness, and claim construction. The narrow sequence and plasmid claims were more defensible but covered fewer design alternatives.

Today, the estate’s practical strength is zero as an exclusionary patent right in the United States because the patent has expired. Its residual value is evidentiary and historical: it identifies the original disclosed sequences, constructs, vectors, and LFA-3-Ig architecture.

What generic or biosimilar launch scenarios exist?

A follow-on developer would likely pursue one of three paths:

  1. A biosimilar or interchangeable product using an LFA-3-Ig structure closely comparable to alefacept.
  2. A new biologic based on a modified CD2-binding domain, alternative Fc region, or different formulation.
  3. A research or diagnostic reagent using an LFA-3-derived CD2-binding fragment.

The expired patent removes a foundational patent barrier. The remaining launch risks are likely to involve FDA requirements, clinical or pharmacodynamic comparability, immunogenicity, manufacturing validation, and any later patent covering a specific product or use.

Key Takeaways

  • United States Patent 5,547,853 claims LFA-3/CD58-derived CD2-binding peptides, encoding DNA, recombinant host cells, production methods, multimeric proteins, pharmaceutical compositions, diagnostic kits, and Fc fusion proteins.
  • Claims 19 through 23 are the most commercially relevant because they cover LFA-3-derived fusion proteins, including immunoglobulin Fc constructs associated with the alefacept platform.
  • The patent issued August 20, 1996, and its ordinary pre-URAA term placed expiration on August 20, 2013.
  • The patent is expired and does not create current U.S. patent exclusivity.
  • The patent is not a conventional Orange Book barrier, and Paragraph IV litigation is not the principal follow-on pathway for alefacept.
  • No biosimilar to alefacept has been approved by the FDA.
  • Current risk must be assessed against later formulation, manufacturing, method-of-use, regulatory, and biologics patents rather than this expired foundational patent.
  • The patent’s strongest historical claims were the defined fusion-protein and recombinant-DNA claims. Its broad functional peptide claims were more exposed to validity and claim-construction challenges.

FAQs

Is Patent 5,547,853 still enforceable against an LFA-3-Ig product?

No. The patent’s ordinary term expired in 2013, so it cannot independently block a current U.S. LFA-3-Ig product.

Does using an IgG1 Fc region avoid Patent 5,547,853?

No avoidance analysis is necessary for the expired patent. For a later patent, the answer would depend on the exact LFA-3 sequence, Fc sequence, linker, formulation, and manufacturing process.

Did Patent 5,547,853 claim the full-length CD58 protein?

The supplied claims primarily target defined CD2-binding fragments and fusion proteins containing those fragments. They should not be read as a blanket claim to every full-length CD58 molecule.

Is alefacept a small-molecule generic or a biosimilar product?

Alefacept is a recombinant biologic. A follow-on product would generally be evaluated under the biologics framework, not as a conventional small-molecule generic under an abbreviated new drug application.

Can a later patent still create launch risk after Patent 5,547,853 expires?

Yes. Later patents may cover specific formulations, dosing regimens, treatment indications, manufacturing processes, cell lines, purification methods, or modified CD2-binding fusion proteins.

References

  1. United States Patent No. 5,547,853. (1996). LFA-3 polypeptides and uses thereof. United States Patent and Trademark Office.

  2. U.S. Food and Drug Administration. (2003). Amevive (alefacept) prescribing information. FDA.

  3. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. FDA.

  4. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

  5. United States Patent and Trademark Office. (n.d.). Manual of Patent Examining Procedure, patent term provisions. USPTO.

More… ↓

⤷  Start Trial

Details for Patent 5,547,853

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Astellas Pharma Us, Inc. AMEVIVE alefacept For Injection 125036 January 30, 2003 5,547,853 2012-10-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.